logo-loader
viewRedx Pharma Plc

Redx Pharma receives regulatory green light to restart cancer trial

RXC004 is one of a new breed of immune-oncology treatments currently in clinical development

woman researcher working in lab
The early-stage clinical trial will start in the first-half of next year

Redx Pharma PLC (LON:REDX) has confirmed it will restart a Phase I/IIa clinical trial of its lead cancer drug in the first half of next year – but at a much reduced dose.

It follows what it described as a “positive” meeting with the Medicines and Healthcare products Regulatory Agency, the drugs watchdog.

WATCH: Redx Pharma's chief medical officer discusses lead oncology drug RXC004

As well as the newly-proposed lower starting dose of RXC004, there will be a revised study protocol, including enhanced safety monitoring.

If it successfully negotiates this early phase clinical assessment, the drug will then be tested in harness with immune checkpoint inhibitors to target solid tumours such as colorectal cancer.

RXC004 is one of a new breed of immune-oncology treatments currently in clinical development.

The so-called Porcupine inhibitor helps enhance the body’s own immune system to tackle what is known as cold tumours that avoid detection by turning them ‘hot’.

Redx chief executive Lisa Anson said she was “pleased” the previously-suspended trial had received the green light to restart.

“We look forward to submitting our final protocol amendments, with the aim of initiating the next patient in the first half of 2019,” she added.

“I would like to thank my colleagues at Redx and our clinical investigators for all their hard work that has resulted in our phase I/IIa proposal being positively received by the MHRA.”

Quick facts: Redx Pharma Plc

Price: 7.5 GBX

AIM:REDX
Market: AIM
Market Cap: £9.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

on 19/11/19

RNS

Form 8.5 (EPT/RI)

6 hours, 3 minutes ago

Form 8.3 - Redx Pharma plc

9 hours, 15 minutes ago

Form 8.3 - RedX Pharma PLC

1 day, 4 hours ago

Form 8.5 (EPT/RI)

1 day, 6 hours ago

Result of General Meeting

2 days, 4 hours ago

Form 8.3 - Redx Pharma PLC

1 week, 1 day ago

2 min read